Roivant Sciences
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $1,442 | $2,520 | $1,999 | $1,571 |
Gross Profit | 1,158 | 2,200 | 1,299 | 1,460 |
EBITDA | -288,273 | 454,735 | -289,678 | -158,123 |
EBIT | -294,564 | 454,097 | -290,369 | -159,044 |
Net Income | -189,831 | 302,994 | -265,891 | -113,519 |
Net Change In Cash | 1,442 | 2,520 | 1,999 | 1,571 |
Free Cash Flow | -263,814 | -165,079 | -191,549 | -193,512 |
Cash | 1,248,456 | 1,423,090 | 1,478,270 | 1,237,010 |
Basic Shares | 720,776 | 812,287 | 696,859 | 680,947 |
Annual Financials
| Values in thousands | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
Revenue | $8,260 | $29,053 | $32,713 | $31,530 |
Gross Profit | 6,975 | 28,142 | 31,114 | 28,496 |
EBITDA | -261,230 | -667,519 | 4,624,670 | -838,165 |
EBIT | -264,578 | -681,590 | 4,602,634 | -857,022 |
Net Income | -299,771 | -171,981 | 4,348,926 | -1,009,030 |
Net Change In Cash | 8,260 | 29,053 | 32,713 | 31,530 |
Cost of Revenue | -388,200 | |||
Free Cash Flow | -758,558 | -844,050 | -766,650 | -856,083 |
Cash | 1,423,090 | 2,715,411 | 6,535,706 | 1,676,813 |
Basic Shares | 693,864 | 725,396 | 831,049 | 712,791 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.45 |
2026-03-31 | -$0.32 |
2025-12-31 | -$0.24 |
2025-09-30 | -$0.28 |